key: cord-0899647-yjklbfsp authors: Psotka, Mitchell A.; Abraham, William T.; Fiuzat, Mona; Filippatos, Gerasimos; Lindenfeld, JoAnn; Ahmad, Tariq; Bhatt, Ankeet S.; Carson, Peter E.; Cleland, John G.F.; Felker, G. Michael; Januzzi, James L.; Kitzman, Dalane W.; Leifer, Eric S.; Lewis, Eldrin F.; McMurray, John J.V.; Mentz, Robert J.; Solomon, Scott D.; Stockbridge, Norman; Teerlink, John R.; Vaduganathan, Muthiah; Vardeny, Orly; Whellan, David J.; Wittes, Janet; Anker, Stefan D.; O'Connor, Christopher M. title: Conduct of Clinical Trials in the Era of COVID-19: JACC Scientific Expert Panel date: 2020-11-17 journal: J Am Coll Cardiol DOI: 10.1016/j.jacc.2020.09.544 sha: 2b0f89ee83cd7fdc550ed09e00e817568bce5bce doc_id: 899647 cord_uid: yjklbfsp The coronavirus disease-2019 (COVID-19) pandemic has profoundly changed clinical care and research, including the conduct of clinical trials, and the clinical research ecosystem will need to adapt to this transformed environment. The Heart Failure Academic Research Consortium is a partnership between the Heart Failure Collaboratory and the Academic Research Consortium, composed of academic investigators from the United States and Europe, patients, the U.S. Food and Drug Administration, the National Institutes of Health, and industry members. A series of meetings were convened to address the challenges caused by the COVID-19 pandemic, review options for maintaining or altering best practices, and establish key recommendations for the conduct and analysis of clinical trials for cardiovascular disease and heart failure. This paper summarizes the discussions and expert consensus recommendations. T he coronavirus disease-2019 (COVID- 19) pandemic has dramatically altered health care delivery and clinical research worldwide. Clinical trial activity apart from COVID-19 studies has plummeted. In April 2020, approximately 90% of clinical trial sites closed to enrollment worldwide, with a 95% decline in cardiovascular trial activity (1, 2) . The rapid initiation of over 1,000 COVID-19 clinical trials contrasts with the decline in non-COVID-19 research. In response to these issues, regulators, sponsors, and professional organizations including the U.S. (3) (4) (5) (6) . These statements promote the principles of safety for patients and research team members while striving to preserve trial integrity (7) . Strategies to limit in-person data collection and maintain physical distancing are suggested. In response, trial telehealth and remote monitoring protocol amendments have surged (8) . Nevertheless, although new regulatory and governmental guidance documents may facilitate remote and electronic data collection, specific methodologies and standardized practices have not been established (6, 7) . The HF Collaboratory (HFC) is a multistakeholder organization that seeks to improve evidence generation for new therapies, implementation of safe and effective treatments, and clinical trial efficiency; HFC includes patients, clinicians, clinical investigators, the FDA, NIH, industry, and payers (9) . The Heart Failure Academic Research Consortium (HF-ARC) working group was convened through a partnership between the HFC and ARC, with representatives from the United States and Europe, to develop a scientific expert statement of standardized methods for heart failure (HF) clinical trials in response to the COVID-19 pandemic. The methods for adjudicating consensus are Table 1 . These recommendations focus largely on data collection and analysis (3) (4) (5) 7) . Sponsors and regulators must together decide which protocol procedures can be safely and accurately completed and which data are critical, and seek to maximize evidence acquisition while embracing flexibility, including protocol amendments and deviations when appropriate. When necessary, collection of imperfect data is preferred to noncollection to minimize difficulties with interpretability and statistical assessment arising from missing data. Case report forms may require specific fields for COVID-19-focused elements to facilitate understanding of the pandemic's impact, including on enrollment, investigational product delivery, follow-up completeness, safety assessments, event rates, and to assist clinical event committee adjudications (an example can be found in the Supplemental Appendix). Regional and country-specific The COVID-19 pandemic has profoundly affected patient care and the conduct of clinical trials. HF-ARC scientific expert panel developed recommendations for the conduct and analysis of heart failure trials during the pandemic. The HF-ARC consensus recommendations support ongoing clinical trials and strengthen the clinical trial ecosystem, which should have sustained benefits in the future. Psotka et al. tion is associated with increased circulating levels, and they are risk markers for severe COVID-19 disease and worse outcomes (28, 29 Changes in cardiovascular event rates in response to COVID-19, and the adjudication and analysis of these events, will be complex ( Table 2) . to the issues covered in this paper, including remote endpoint collection, methods to minimize missing data, and SAP modifications. Januzzi is a trustee of the American College of Cardiology; has received grant support from Applied Therapeutics, Novartis Pharmaceuticals, and Abbott Diagnostics; has received consulting income from Abbott Lewis has received consulting fees from Novartis; and has received institutional research grant support from Amgen Mentz has received consulting fees from Abbott National Institutes of Health grants U01HL125511-01A1 and R01AG045551-01A1. Dr. Solomon has received research grants from National Institutes of Health/ National Heart, Lung, and Blood Institute, Novartis, Sanofi Pasteur, and Theracos; and has received consulting fees from Akros Teerlink has received consulting fees from Amgen, Bayer, Cytokinetics, Novartis, and Stealth Health; and has received research funding from Abbott, Amgen, Bayer, Bristol Myers Squibb, Novartis, and scPharmaceuticals. Dr. Vaduganathan is supported by the KL2/Catalyst Medical Research Investigator Training award from Harvard Catalyst (NIH/ NCATS Award UL 1TR002541) Vardeny has received consulting fees from Novartis; and has received research grants from AstraZeneca and Sanofi Pasteur. Dr. Whellan has received grant support from the Wittes reports that the company for which she works, Statistics Collaborative, has contracts with many companies, some of which are developing treatments for heart failure. Dr. Anker has received clinical trial-related fees from Abbott Vascular has received research support from Roche Diagnostics and Merck; has been a consultant for Bristol Myers Squibb, Merck, Windtree, and Neurotronik; and is a co-owner of Biscardia Division of Cardiovascular Medicine Twitter: @hfcollaboratory, @coconnormd, @mfiuzat, @jteerlinkmd, @mpsotka COVID-19 and Clinical Trial Operations Medidata. COVID 19 and Clinical Trials: The Medidata Perspective FDA Guidance on Conduct of Clinical Trials of Medical Products During COVID-19 Public Health Emergency Guidance for NIHfunded Clinical Trials and Human Subjects Studies Affected by COVID-19 Guidance on the Management of Clinical Trials during the COVID-19 (Coronavirus) Pandemic. 2020. Available at Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) Heart Failure Collaboratory statement on clinical trials in the landscape of COVID-19 Remote Monitoring, Protocol Amendments Spike With COVID-19 Spread Improving heart failure therapeutics development in the United States: the Heart Failure Collaboratory Department of Health and Human Services, Food and Drug Administration. E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1): Guidance for Industry Unannounced telephone pill counts for assessing varenicline adherence in a pilot clinical trial A statistical approach to central monitoring of data quality in clinical trials Patient-reported outcomes in chronic heart failure: applicability for regulatory approval Medical Device Development Tools (MDDT) Impact of telemonitoring on health status Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction Physician vs patient assessment of dyspnea during acute decompensated heart failure Ferric carboxymaltose in patients with heart failure and iron deficiency Pixel or paper? Validation of a mobile technology for collecting patient-reported outcomes in rheumatoid arthritis Self-assessed Isosorbide mononitrate in heart failure with preserved ejection fraction The mobile-based 6-minute walk test: usability study and algorithm development and validation Differences in how a step is detected among three popular activity monitors that have impacted physical activity research Association of implantable device measured physical activity with hospitalization for heart failure Recommendations for echocardiography laboratories participating in cardiac point of care cardiac ultrasound (pocus) and critical care echocardiography training: report from the American Society of Echocardiography Natriuretic peptides as inclusion criteria in clinical trials: a JACC: heart failure position paper Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19) Myocardial localization of coronavirus in COVID-19 cardiogenic shock Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 -COVID-NET, 14 states Population trends in rates of percutaneous coronary revascularization for acute coronary syndromes associated with the COVID-19 outbreak Reduction in ST-segment elevation cardiac catheterization laboratory activations in the United States during COVID-19 pandemic Reductions in heart failure hospitalizations during the COVID-19 pandemic Out-of-hospital cardiac arrest during the Covid-19 outbreak in Italy Internet/Broadband Fact Sheet Determining the Extent of Safety Data Collection Needed in Late-Stage Premarket and Postapproval Clinical Investigations -Guidance for Industry Variation in COVID-19 Hospitalizations and Deaths Across New York City Boroughs Age Adjusted Rate of Fatal Lab Confirmed COVID-19 Cases per 100,000 by Race/ Ethnicity Group